Venker Eric 4
4 · Roivant Sciences Ltd. · Filed Jan 14, 2026
Insider Transaction Report
Form 4
Venker Eric
President & Immunovant CEO
Transactions
- Exercise/Conversion
Common Shares
2026-01-12$3.85/sh+200,000$770,000→ 1,854,597 total - Sale
Common Shares
[F1]2026-01-12$21.92/sh−200,000$4,384,000→ 1,654,597 total - Exercise/Conversion
Stock Option (Right to Buy)
[F2]2026-01-12−200,000→ 5,244,834 totalExercise: $3.85Exp: 2032-04-19→ Common Stock (200,000 underlying)
Footnotes (2)
- [F1]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.59 to $22.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
- [F2]Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).
Signature
By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker|2026-01-14